1.00
0.04 (4.17%)
| Penutupan Terdahulu | 0.960 |
| Buka | 1.01 |
| Jumlah Dagangan | 35,604 |
| Purata Dagangan (3B) | 698,970 |
| Modal Pasaran | 6,103,810 |
| Harga / Buku (P/B) | 4.11 |
| Julat 52 Minggu |
| EPS Cair (TTM) | -1.43 |
| Nisbah Semasa (MRQ) | 0.180 |
| Aliran Tunai Operasi (OCF TTM) | -4.43 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -3.69 M |
| Pulangan Atas Aset (ROA TTM) | -188.95% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menurun | Menurun |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | Channel Therapeutics Corporatio | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | -2.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -2.5 |
| Purata | -1.00 |
|
Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 53.87% |
| % Dimiliki oleh Institusi | 13.60% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 14 May 2025 | Pengumuman | Channel Therapeutics Announces Positive Efficacy Results for the Treatment of Eye Pain Using its NaV1.7 Inhibitor in Multiple Preclinical In Vivo Models |
| 01 May 2025 | Pengumuman | Channel Therapeutics Provides Announcement on 2024 Annual Report to Comply with NYSE American Listing Rules |
| 17 Apr 2025 | Pengumuman | Ligand Subsidiary Pelthos Therapeutics to Combine with Channel Therapeutics |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |